Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

36.13
-0.0300-0.08%
Volume:199.36K
Turnover:7.21M
Market Cap:3.49B
PE:-7.68
High:36.45
Open:36.05
Low:35.98
Close:36.16
52wk High:72.66
52wk Low:35.06
Shares:96.64M
Float Shares:95.45M
Volume Ratio:0.33
T/O Rate:0.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7061
EPS(LYR):-4.3646
ROE:-43.62%
ROA:-28.02%
PB:2.81
PE(LYR):-8.28

Loading ...

Aug 09, 2023

Major Issues Report

Form 8-K - Current report
Aug 09, 2023

Major Issues Report

Form 8-K - Current report
Aug 09, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jun 02, 2023

Major Issues Report

Form 8-K - Current report
Jun 01, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 31, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 30, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 24, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 09, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 09, 2023

Major Issues Report

8-K - Current report
Mar 14, 2023

Major Issues Report

8-K - Current report
Mar 08, 2023

Major Issues Report

8-K - Current report
Mar 01, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 01, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Nov 08, 2022

Major Issues Report

8-K - Current report
Nov 08, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]